The recent approval of nerandomilast (Jascayd) by the Medicines and Healthcare products Regulatory Agency (MHRA) marks a significant development in the treatment of Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF). This groundbreaking medication, which was granted marketing authorization on July 8, 2026, offers a new treatment option for adults suffering from these debilitating lung conditions. IPF and PPF are characterized by the gradual scarring of lung tissue, leading to severe breathing difficulties. Nerandomilast, with its active ingredient, aims to regulate the immune system and reduce lung tissue scarring, providing a glimmer of hope for patients. The recommended dosage is an 18mg tablet, taken orally twice daily, and it can only be obtained with a prescription. While the MHRA's approval is a crucial step, it's important to note that the safety and effectiveness of nerandomilast will be closely monitored. The most common side effects, affecting more than 1 in 10 people, include diarrhea and weight loss. Patients are encouraged to report any side effects to the Yellow Card scheme for further analysis. This development is particularly noteworthy as it addresses an unmet clinical need, ensuring that patients with IPF and PPF have access to safe and effective treatments. Julian Beach, MHRA Executive Director, emphasizes the agency's commitment to patient safety and the evaluation of new medicines. The MHRA's role in regulating medicines and medical devices in the UK is vital, ensuring that the benefits of treatments outweigh any potential risks. As the MHRA continues to review nerandomilast, this approval paves the way for improved management of IPF and PPF, offering a beacon of hope for those affected by these challenging lung conditions. The availability of this new treatment is a significant step forward in the fight against IPF and PPF, and it highlights the importance of ongoing research and development in the field of medicine.
